MRKR
Marker Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.20
+15.38%Year over year
Reported trailing growth
- Revenue
- -77.1%
- EBITDA
- +7.4%
- EBIT
- +29.2%
- EPS
- +65.0%
- Free cash flow
- +10.4%
- Operating cash flow
- +10.4%
Forward estimates
Based on analyst estimates
- Revenue
- +250.0%
- EBITDA
- -69.4%
- EPS
- -87.5%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- -16.4%
- EBIT
- -15.9%
- Net income
- -13.3%
- EPS
- +33.6%
- Free cash flow
- -10.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026